EXKIVITY Drug Patent Profile

When do Exkivity patents expire, and what generic alternatives are available?

Exkivity is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are two patents protecting this drug.

This drug has sixty-five patent family members in forty countries.

The generic ingredient in EXKIVITY is mobocertinib succinate. Additional details are available on the mobocertinib succinate profile page.

DrugPatentWatch^® Generic Entry Outlook for Exkivity

Exkivity was eligible for patent challenges on September 15, 2025.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 15, 2028. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for EXKIVITY

International Patents:	65
US Patents:	2
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	54
Patent Applications:	64
Drug Prices:	Drug price information for EXKIVITY
What excipients (inactive ingredients) are in EXKIVITY?	EXKIVITY excipients list
DailyMed Link:	EXKIVITY at DailyMed

See drug prices for EXKIVITY

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for EXKIVITY

Constraining patent/regulatory exclusivity:

TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 20 INSERTION MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST, WHOSE DISEASE HAS PROGRESSED ON OR AFTER PLATINUM-BASED CHEMOTHERAPY

NDA:

215310

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for EXKIVITY

EXKIVITY is protected by two US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 20 INSERTION MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST, WHOSE DISEASE HAS PROGRESSED ON OR AFTER PLATINUM-BASED CHEMOTHERAPY.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	EXKIVITY	mobocertinib succinate	CAPSULE;ORAL	215310-001	Sep 15, 2021		DISCN	Yes	No			Y	Y
Takeda Pharms Usa	EXKIVITY	mobocertinib succinate	CAPSULE;ORAL	215310-001	Sep 15, 2021		DISCN	Yes	No
Takeda Pharms Usa	EXKIVITY	mobocertinib succinate	CAPSULE;ORAL	215310-001	Sep 15, 2021		DISCN	Yes	No			Y	Y
Takeda Pharms Usa	EXKIVITY	mobocertinib succinate	CAPSULE;ORAL	215310-001	Sep 15, 2021		DISCN	Yes	No

International Patents for EXKIVITY

When does loss-of-exclusivity occur for EXKIVITY?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cuba

Cyprus

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

Georgia, Republic of

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

Montenegro

Morocco

New Zealand

Peru

Philippines

Poland

Portugal

San Marino

Saudi Arabia

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Tunisia

Turkey

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering EXKIVITY around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2015277786
Australia	2019206024
Brazil	112016029662
Canada	2949793
Chile	2016003222
Chile	2017003103

Supplementary Protection Certificates for EXKIVITY

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3157916	C03157916/01	Switzerland		PRODUCT NAME: MOBOCERTINIB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68147 01.06.2022
3157916	SPC/GB22/041	United Kingdom		PRODUCT NAME: MOBOCERTINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, FOR EXAMPLE, MOBOCERTINIB SUCCINATE; REGISTERED: UK PLGB 16189/0124-0001 20220317

EXKIVITY Market Dynamics and Financial Trajectory: Mobocertinib Withdrawal, Patent Risk, and Commercial Outlook

Last updated: August 18, 2026

EXKIVITY, the brand name for mobocertinib, moved from accelerated FDA approval in 2021 to U.S. market withdrawal in 2024 after failure of its required confirmatory trial. The drug targeted adults with locally advanced or metastatic non-small cell lung cancer whose tumors had EGFR exon 20 insertion mutations and whose disease progressed after platinum-based chemotherapy.

The commercial opportunity was narrow, the competitive field expanded rapidly, and confirmatory evidence did not support continued U.S. approval. EXKIVITY therefore has no meaningful forward commercial trajectory in the United States. Its remaining value is primarily historical, regulatory, litigation, and intellectual-property related.

What is EXKIVITY and which patients did it target?

EXKIVITY is an oral kinase inhibitor containing mobocertinib. Takeda developed and commercialized the drug for EGFR exon 20 insertion mutation-positive non-small cell lung cancer, a molecularly defined subset of lung cancer with limited treatment options at the time of launch.

The FDA granted accelerated approval on September 15, 2021. The approved indication covered adults with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations whose disease had progressed on or after platinum-based chemotherapy.[1]

The approval was based primarily on an overall response rate of 28% in a platinum-pretreated cohort. The median duration of response was 17.5 months.[1] The approval was conditional on a confirmatory trial demonstrating clinical benefit.

EXKIVITY product profile

Attribute	Details
Active ingredient	Mobocertinib
Brand	EXKIVITY
Developer	Takeda Pharmaceutical Company
Drug class	Oral EGFR tyrosine kinase inhibitor
Target	EGFR exon 20 insertion mutations
Dosage form	Oral capsules
FDA approval	September 15, 2021
FDA pathway	Accelerated approval
Primary indication	Previously platinum-treated locally advanced or metastatic NSCLC
Confirmatory study	EXCLAIM-2
U.S. withdrawal	Effective February 15, 2024

Why was EXKIVITY withdrawn from the U.S. market?

EXKIVITY was withdrawn after the EXCLAIM-2 confirmatory trial failed its primary endpoint. The study compared mobocertinib with platinum-based chemotherapy in patients with untreated EGFR exon 20 insertion-positive advanced or metastatic NSCLC.

The trial did not demonstrate a statistically significant progression-free survival benefit. Takeda announced that it would voluntarily withdraw EXKIVITY globally, and the FDA published the withdrawal notice for the U.S. indication.[2,3]

The sequence was:

Date	Event
September 2021	FDA grants accelerated approval
2022-2023	Confirmatory EXCLAIM-2 trial fails its primary endpoint
October 2023	Takeda announces global withdrawal plans
February 15, 2024	U.S. withdrawal becomes effective

The withdrawal removed the product from active U.S. commercial competition. It also eliminated the principal basis for future U.S. revenue growth.

What was the financial trajectory of EXKIVITY?

EXKIVITY generated limited commercial revenue relative to Takeda’s portfolio. Takeda did not consistently report EXKIVITY as a standalone material revenue line in its public financial reporting. Product-specific sales were therefore not disclosed with the precision available for major Takeda products such as ENTYVIO, TAKHZYRO, or TRINTELLIX.[4]

The financial trajectory can be characterized in four stages:

1. Pre-launch investment and regulatory development.
2. Initial launch revenue after the 2021 accelerated approval.
3. Commercial constraint caused by the narrow EGFR exon 20 insertion population and competing therapies.
4. Revenue contraction and discontinuation following the failed confirmatory trial.

Revenue drivers

EXKIVITY had several structural limitations:

• The eligible population was a small molecular subgroup of NSCLC.
• The FDA approval required prior platinum-based chemotherapy.
• The drug had to compete with chemotherapy and emerging targeted therapies.
• Accelerated approval created a continuing evidence obligation.
• U.S. withdrawal eliminated the largest regulated market opportunity.
• Treatment-related adverse events could affect persistence and prescribing.

Takeda’s public filings treated EXKIVITY as a growth product within oncology, but the product did not develop into a major revenue contributor. The company’s financial exposure was more significant in development, launch, manufacturing, regulatory, and commercial infrastructure costs than in lost portfolio revenue after withdrawal.

Financial impact of withdrawal

The withdrawal reduced future product revenue but also removed ongoing commercialization costs. Takeda could still incur expenses related to:

• Patient transition and supply discontinuation.
• Inventory write-offs.
• Contract termination.
• Regulatory closeout.
• Manufacturing and distribution wind-down.
• Potential impairment of acquired or developed intangible assets.

Takeda’s reported financial statements should be used for impairment and aggregate oncology analysis. They do not establish a reliable standalone lifetime revenue figure for EXKIVITY.[4]

How large was the EXKIVITY market opportunity?

The target market was medically important but commercially constrained. EGFR exon 20 insertion mutations account for a small percentage of EGFR-mutated NSCLC cases. The eligible population was further narrowed by the requirement for progression after platinum chemotherapy under the original FDA label.

Market size depended on four variables:

Variable	Effect on EXKIVITY
EGFR exon 20 insertion testing	Expanded the diagnosed addressable population
Platinum-treatment sequencing	Delayed treatment until later-line use
Duration of therapy	Supported recurring oral-drug revenue
Competitive entry	Reduced share and pricing power

EXKIVITY entered a market in which physicians needed an effective targeted option, but the commercial opportunity was smaller than for broad EGFR inhibitors such as osimertinib. The product did not have the population scale associated with EGFR exon 19 deletion or L858R therapies.

How did EXKIVITY compare with competing treatments?

EXKIVITY competed against chemotherapy, clinical trials, and targeted therapies for EGFR exon 20 insertion-positive NSCLC. The most important commercial competitor was RYBREVANT, or amivantamab, developed by Johnson & Johnson and Genmab.

EXKIVITY versus RYBREVANT

Category	EXKIVITY	RYBREVANT
Active ingredient	Mobocertinib	Amivantamab
Modality	Oral small molecule	Intravenous bispecific antibody
Target	EGFR exon 20 insertion	EGFR and MET
Initial U.S. setting	Post-platinum	First approved after platinum chemotherapy
FDA status	Withdrawn February 2024	Active U.S. product
Administration	Oral capsules	Infusion-based
Commercial limitation	Narrow indication and efficacy concerns	Infusion burden and administration resources
Competitive position after 2024	No active U.S. commercial position	Primary established targeted competitor

RYBREVANT received accelerated approval in May 2021 for adults with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations whose disease had progressed on or after platinum-based chemotherapy.[5]

The launch timing gave RYBREVANT and EXKIVITY overlapping post-platinum positions. RYBREVANT’s first-mover status, physician familiarity, and continued regulatory presence strengthened its commercial position after EXKIVITY’s withdrawal.

Other competitors included platinum chemotherapy, docetaxel-based regimens, clinical trials, and investigational next-generation EGFR exon 20 inhibitors. The competitive environment made confirmatory efficacy especially important.

What regulatory exclusivity did EXKIVITY receive?

EXKIVITY received accelerated approval rather than traditional approval. Accelerated approval can permit earlier commercialization based on a surrogate endpoint, but it requires a post-approval study to verify clinical benefit.

The regulatory framework created a direct commercial risk. If the confirmatory study failed, the FDA could require withdrawal or the sponsor could voluntarily remove the product. That is what occurred with EXKIVITY.[2]

EXKIVITY’s commercial exclusivity was therefore less durable than that of a product supported by a completed confirmatory program. FDA approval did not guarantee a full long-term market window.

Pediatric and orphan-drug considerations

The FDA approval materials should be reviewed for any applicable orphan-drug, pediatric, or other regulatory exclusivity. These protections would not preserve U.S. sales after the approved indication was withdrawn. Regulatory exclusivity also does not prevent a product from being removed when the required clinical benefit is not confirmed.

What patents protect EXKIVITY and mobocertinib?

Mobocertinib is a small-molecule drug, so its protection depends on chemical composition, pharmaceutical composition, formulation, and use patents rather than biologic exclusivity.

Potential protection categories include:

• Compound claims covering mobocertinib or related chemical structures.
• Salt, stereochemical, or crystalline-form claims.
• Pharmaceutical-composition claims.
• Oral dosage-form claims.
• Methods of treating EGFR exon 20 insertion-positive NSCLC.
• Biomarker-defined patient-selection claims.
• Manufacturing and process claims.

The relevant patent holder and commercial rights were associated with Takeda following its acquisition of ARIAD Pharmaceuticals. Patent protection may continue after product withdrawal, but its practical value falls sharply when the approved product is no longer marketed.

Orange Book status

EXKIVITY was an FDA-approved small-molecule product and therefore fell within the Orange Book framework. Orange Book listings can include patents claiming the drug substance, drug product, or approved method of use. Withdrawal of an NDA does not automatically mean every related patent expires or becomes unenforceable.

The commercial significance of Orange Book patents is now limited because there is no active U.S. branded product generating a near-term generic substitution market. A generic applicant could still evaluate an abbreviated new drug application strategy if Takeda later sought to relaunch the drug or if a remaining indication supported marketing.

When does EXKIVITY lose exclusivity?

EXKIVITY lost its practical U.S. market exclusivity when the product was withdrawn on February 15, 2024. That date is more commercially important than any nominal patent-expiration date.

A patent can remain in force after product withdrawal, but it cannot protect active sales that no longer exist. Future exclusivity value would require one of the following:

• Reinstatement of the U.S. indication.
• Approval of a new indication.
• Reintroduction supported by new clinical evidence.
• Licensing to another company.
• Development of a differentiated formulation or combination regimen.

No such commercial pathway was established in the FDA withdrawal notice or Takeda’s public withdrawal announcements.[2,3]

Were there Paragraph IV challenges or generic litigation?

There was no major publicly established Paragraph IV litigation campaign associated with EXKIVITY comparable to the generic challenges affecting high-revenue small-molecule products.

That outcome is commercially rational. Generic companies generally pursue Paragraph IV litigation when the expected future market is large enough to justify patent-certification, litigation, and launch costs. EXKIVITY’s narrow indication, limited sales, and U.S. withdrawal reduced the incentive for a generic challenge.

The absence of prominent Paragraph IV litigation does not mean the patent estate was irrelevant. It means the expected generic opportunity was insufficiently attractive during the product’s commercial life.

What formulation and method-of-use protection did EXKIVITY have?

The strongest commercial protection for EXKIVITY was its FDA-approved use in a genetically defined cancer population. Method-of-use claims tied to EGFR exon 20 insertion-positive NSCLC could have supported branded positioning if the product remained approved.

Formulation protection was less commercially decisive because mobocertinib was administered as an oral capsule, a conventional delivery format. No complex device, depot formulation, or biologic manufacturing process created a major barrier to generic development.

The most important technical barrier was clinical validation, not manufacturing complexity. A generic manufacturer could potentially reproduce a conventional oral small-molecule product, subject to patent, regulatory, and bioequivalence requirements.

Which companies challenged or replaced EXKIVITY?

No major company needed to challenge EXKIVITY through litigation after Takeda withdrew it. The competitive displacement occurred through clinical and regulatory competition.

Key companies included:

Company	Product or role	Strategic relevance
Takeda	EXKIVITY/mobocertinib	Original developer and marketer
Johnson & Johnson and Genmab	RYBREVANT/amivantamab	Established targeted competitor
Daiichi Sankyo and AstraZeneca	Investigational EGFR-directed programs	Potential next-generation competition
Other oncology developers	EGFR exon 20 insertion programs	Pipeline competition and clinical-trial alternatives

The market shifted from a two-product targeted segment toward a market led by continuing therapies and newer clinical programs.

What generic entry risks exist for EXKIVITY?

The immediate generic-entry risk is low because the branded product is no longer commercially active in the United States. A future generic launch would require a viable reference-product and market strategy.

The principal risks are:

• Patent claims covering mobocertinib or its approved uses.
• Regulatory requirements associated with a withdrawn product.
• Limited physician demand.
• Small eligible patient population.
• Competing targeted therapies.
• Lack of a current U.S. commercial channel.

If Takeda or another sponsor obtained a new approval, the risk profile would change. In that scenario, remaining compound, formulation, and method-of-use patents could become relevant again.

What is the geographic coverage of EXKIVITY?

EXKIVITY’s commercial geography narrowed after Takeda announced global withdrawal plans. The United States was the most clearly documented withdrawal market because the FDA withdrawal became effective February 15, 2024.[2]

Takeda’s global withdrawal announcement indicated that the company would discontinue the product in other markets, subject to local regulatory requirements.[3] Market access, reimbursement, and withdrawal timing could vary by jurisdiction.

The product’s geographic value was therefore limited by:

• Withdrawal from the United States.
• Discontinuation plans in other markets.
• Small biomarker-defined demand.
• Dependence on local EGFR testing.
• Availability of alternative EGFR exon 20 treatments.

How strong is the EXKIVITY patent estate?

The EXKIVITY patent estate has limited current commercial strength. Patent duration alone cannot offset the loss of an active approved market.

Its practical strength can be assessed across four dimensions:

Dimension	Assessment
Compound protection	Potentially meaningful while relevant claims remain enforceable
Formulation protection	Likely less significant for a conventional oral capsule
Method-of-use protection	Potentially important for biomarker-defined treatment
Commercial enforceability	Low current value after U.S. withdrawal

The estate could retain defensive value in licensing, litigation, or future redevelopment. It does not currently support a substantial U.S. revenue stream.

What litigation and settlement agreements affect EXKIVITY?

No major settlement agreement or patent settlement drove the product’s market outcome. The decisive event was the failed confirmatory trial and the resulting withdrawal.

The main legal exposure after withdrawal would relate to:

• Product-liability claims.
• Regulatory compliance.
• Contract termination.
• Patent disputes if a future relaunch occurred.
• Licensing or asset-transfer negotiations.

There is no publicly established settlement framework that materially changes EXKIVITY’s post-withdrawal commercial outlook.

What is the future commercial outlook for EXKIVITY?

EXKIVITY has no credible near-term U.S. growth trajectory. Its market opportunity ended when Takeda withdrew the product and the confirmatory trial failed.

Potential residual value exists in:

• Research use of mobocertinib.
• Combination therapy development.
• Geographic re-registration.
• Licensing of patent rights.
• Use as a benchmark in EGFR exon 20 drug development.
• Repurposing or reformulation, if supported by new clinical data.

Each pathway would require new investment and evidence. The original accelerated approval does not provide a durable foundation for re-entry.

Key Takeaways

• EXKIVITY is mobocertinib, an oral EGFR inhibitor for EGFR exon 20 insertion-positive NSCLC.
• The FDA granted accelerated approval on September 15, 2021.
• The confirmatory EXCLAIM-2 study failed its primary progression-free survival endpoint.
• U.S. withdrawal became effective February 15, 2024.
• Takeda did not report a reliable standalone lifetime revenue figure for EXKIVITY.
• The product’s target population was narrow, limiting peak sales potential.
• RYBREVANT became the leading continuing targeted competitor after EXKIVITY’s withdrawal.
• Generic and Paragraph IV risk was limited by the product’s small market and commercial discontinuation.
• Patent rights may remain legally active, but their present commercial value is low.
• Any future value would depend on relaunch, licensing, new indications, or new clinical evidence.

Frequently Asked Questions

Could EXKIVITY return to the U.S. market?

A return would require a new regulatory strategy and clinical evidence sufficient to support approval or reapproval. The original accelerated approval and failed confirmatory trial do not provide a viable standalone basis for relaunch.

Did EXKIVITY receive full FDA approval?

No. EXKIVITY received accelerated approval based on response-rate data. The confirmatory trial required to verify clinical benefit failed its primary endpoint.

Is mobocertinib still useful in EGFR exon 20 insertion cancer research?

Yes. Mobocertinib remains relevant as a clinical benchmark and research compound, even though commercial U.S. treatment access ended with withdrawal.

Does EXKIVITY have biosimilar risk?

No. Mobocertinib is a chemically synthesized small molecule, not a biologic. The relevant competitive risk is generic-drug entry, not biosimilar substitution.

Why did EXKIVITY fail commercially despite addressing an unmet need?

Its commercial potential was constrained by a small biomarker-defined population, later-line positioning, competition from RYBREVANT, and failure of the required confirmatory trial.

References

1. U.S. Food and Drug Administration. (2021, September 15). FDA grants accelerated approval to mobocertinib for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations. https://www.fda.gov
2. U.S. Food and Drug Administration. (2024, February 15). Withdrawal of approval of new drug application for EXKIVITY (mobocertinib). Federal Register. https://www.federalregister.gov
3. Takeda Pharmaceutical Company Limited. (2023, October 25). Takeda provides update on EXKIVITY (mobocertinib) withdrawal. https://www.takeda.com
4. Takeda Pharmaceutical Company Limited. (2024). Annual report 2024. https://www.takeda.com/investors/financial-results/
5. U.S. Food and Drug Administration. (2021, May 21). FDA grants accelerated approval to amivantamab-vmjw for metastatic non-small cell lung cancer. https://www.fda.gov

DrugChatter Q&A for EXKIVITY

Is exkivity still on the market?
What are the side effects of Exkivity?